CRISPR Therapeutics to Participate in Upcoming Investor Conferences
February 08, 2023 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
January 11, 2023 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
December 19, 2022 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®
December 12, 2022 10:00 ET
|
CRISPR Therapeutics AG
-Update provided for both Part A (single dose with optional re-dosing) and Part B (consolidation dosing) of the Phase 1 CARBON™ clinical trial- -Part A data presented at the 64th American Society...
CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference
December 01, 2022 08:00 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 10, 2022 17:40 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
November 03, 2022 09:06 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 01, 2022 16:01 ET
|
CRISPR Therapeutics AG
-Exagamglogene autotemcel (exa-cel), formerly known as CTX001™ submission to the U.S. Food and Drug Administration (FDA) for rolling review expected to begin in November, with completion of the U.S....
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
October 27, 2022 08:30 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022 08:05 ET
|
CRISPR Therapeutics AG
ZUG, Switzerland and BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...